KY1 completes first patient dosing in Phase I clinical trial

2024-10-25

Russian Academy of Engineering Foreign Academician Dr. Zhang Dan was Invited to Visit and Guide Clinical Trials

2024-10-25

KeYe Biotech Successfully Holds KY1 Product Clinical Trial Kickoff Meeting

2024-10-25

KeYe Biotech Receives "High Growth Enterprise" Designation

2024-10-25

KeYe Life's KY1 molecule has received orphan drug designation (ODD) from the FDA for gastric cancer

2024-10-22

KeYe Life's KY1 molecule has received orphan drug designation from the FDA for hepatocellular carcinoma

2024-10-22

The paper by KeYe Life Sciences titled "An RNA Helicase DHX33 Inhibitor Shows Broad Anticancer Activity via Inducing Ferroptosis in Cancer Cells" has been published in the ACS Omega journal of the American Chemical Society

2024-10-22

KeYe Life, an innovative biotech company, has independently developed a small-molecule drug targeting RNA helicase, which has recently received clinical trial approval from the China Center for Drug Evaluation (CDE).

2024-10-22

The paper by Keye Life Sciences’ team, titled "DHX33 mediates p53 to regulate mevalonate pathway gene transcription in human cancers," has been published in the BBA multidisciplinary journal.

2024-10-22

KeYe Life has obtained certifications in quality, environment, occupational health and safety

2024-10-22